• About
    • Our Story
    • Management
    • Board of Directors
  • Science
  • Pipeline
    • BH-30643
    • BH-30236
    • Posters and Presentations
  • Clinical Trials
  • News
  • Careers
  • Contact
  • Menu Menu

About

At BlossomHill, we are on a mission to develop innovative small molecule medicines with the potential to overcome the limitations of existing therapies or approaches and address significant unmet medical needs in cancer treatment.

OUR STORY | MANAGEMENT | BOARD OF DIRECTORS

Driven by a desire to overcome the limitations of existing drugs, we approach drug design from the ground up. Combining a deep understanding of disease and protein dynamics with our structure-based rational drug design expertise, we are dedicated to developing innovative small-molecule medicines that address significant unmet medical needs in cancer treatment.

patient with hand on shoulder

Our Story

Mountains and ridges, rivers and streams—it seems like there is no road forward; after a turning point, an enchanting village by a BlossomHill is ahead!

Our name, BlossomHill, was inspired by an ancient Chinese poem that describes a challenging journey overcome through perseverance, eventually leading to hope and opportunity. We believe this symbolizes the patient’s journey through treatment.

SEE MORE

At the heart of BlossomHill is J. Jean Cui, Ph.D., a visionary in drug design, whose desire to improve treatment outcomes for patients led her to found our company and build a wholly-owned pipeline of novel therapeutic candidates.

Inspired to leap beyond the incremental progress in precision medicine, Jean’s deep scientific knowledge and artistic approach breathe life into the concept of creating medical masterpieces to treat disease.

J. Jean Cui, Ph.D., Founder, Inventor, and Drug Designer:

Multiple masterpieces are the mark of a prolific artist.

Dr. J. Jean Cui has a proven track record as a cancer drug designer and developer. Dr. Cui is the lead inventor of three FDA-approved targeted cancer therapies: repotrectinib (AUGTYRO®), crizotinib (XALKORI®) and lorlatinib (LORBRENA®). Repotrectinib was the lead program in Turning Point Therapeutics’ pipeline, a company co-founded by Dr. Cui and Peter Li that was acquired by Bristol-Myers Squibb in 2022.

Management

J. Jean Cui, Ph.D.

May 29, 2024
Scientific Founder, President and CEO
https://bhtherapeutics.com/wp-content/uploads/Jean_Cui.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 20:00:412026-07-16 15:04:32J. Jean Cui, Ph.D.

Y. Peter Li, Ph.D., MBA

May 29, 2024
Cofounder and Executive Chairman
https://bhtherapeutics.com/wp-content/uploads/Peter_Li.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 19:00:282026-07-16 15:03:01Y. Peter Li, Ph.D., MBA

Geoff Oxnard, M.D.

May 29, 2024
Executive Vice President and Chief Medical Officer
https://bhtherapeutics.com/wp-content/uploads/Geoff_Oxnard.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 18:00:212026-07-16 17:32:16Geoff Oxnard, M.D.

Vincent Liptak, J.D., Ph.D., MBA

May 29, 2024
Executive Vice President and General Counsel
https://bhtherapeutics.com/wp-content/uploads/Vincent_Liptak.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 17:00:092026-07-16 15:19:17Vincent Liptak, J.D., Ph.D., MBA

Jason Keyes, MBA

May 29, 2024
Executive Vice President and Chief Financial Officer
https://bhtherapeutics.com/wp-content/uploads/Jason_Keyes.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 16:30:322026-07-16 15:20:08Jason Keyes, MBA

Antonio Garrido-Montalban, Ph.D.

May 29, 2024
Senior Vice President, Drug Substance
https://bhtherapeutics.com/wp-content/uploads/Antonio_Garrido-Montalban.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 16:00:212026-07-16 17:33:43Antonio Garrido-Montalban, Ph.D.

Ashley Preston, Ph.D.

May 29, 2024
Senior Vice President, Head of Regulatory Affairs and Quality Assurance
https://bhtherapeutics.com/wp-content/uploads/Ashley_Preston.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 15:30:022026-07-16 15:22:43Ashley Preston, Ph.D.

Eugene Y. Rui, Ph.D.

May 29, 2024
Senior Vice President, Chemistry
https://bhtherapeutics.com/wp-content/uploads/Eugene_Rui.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 15:00:192026-07-16 17:34:18Eugene Y. Rui, Ph.D.

Z. Jesse Shao, Ph.D., R.Ph.

May 29, 2024
Senior Vice President, CMC
https://bhtherapeutics.com/wp-content/uploads/Jesse_Shao.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 14:30:352026-07-16 17:35:13Z. Jesse Shao, Ph.D., R.Ph.

Jill Stuart Smith, MBA

May 29, 2024
Senior Vice President, Clinical Operations and Project Management
https://bhtherapeutics.com/wp-content/uploads/Jill-Stuart-Smith.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 14:00:032026-07-16 15:32:54Jill Stuart Smith, MBA

Diane Wang, Ph.D.

May 29, 2024
Senior Vice President, Clinical Pharmacology and Preclinical Development
https://bhtherapeutics.com/wp-content/uploads/Diane-Wang.jpg 620 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 13:30:592026-07-16 17:36:34Diane Wang, Ph.D.

Zachary F. Zimmerman, M.D., Ph.D.

May 29, 2024
Senior Vice President, Clinical Development
https://bhtherapeutics.com/wp-content/uploads/Zachary_Zimmerman.jpg 625 500 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-29 13:00:402026-07-16 17:37:02Zachary F. Zimmerman, M.D., Ph.D.

Board of Directors

Bihua Chen

https://bhtherapeutics.com/wp-content/uploads/Bihua_Chen.jpg 400 400 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-28 14:05:162026-07-16 15:37:27Bihua Chen

Carl L. Gordon, Ph.D., CFA

https://bhtherapeutics.com/wp-content/uploads/Carl_Gordon.jpg 400 400 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-28 14:00:442026-07-16 15:37:58Carl L. Gordon, Ph.D., CFA

J. Jean Cui, Ph.D.

https://bhtherapeutics.com/wp-content/uploads/Jean_Cui-BOD.jpg 400 400 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-28 13:58:582026-05-20 09:29:47J. Jean Cui, Ph.D.

John Schmid

https://bhtherapeutics.com/wp-content/uploads/John-Schmid-Headshot.webp 400 400 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2024-05-28 13:55:472026-07-16 15:39:47John Schmid

Sheila Gujrathi, M.D.

https://bhtherapeutics.com/wp-content/uploads/Sheila-Gujrathi-Headshot.webp 400 400 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2024-05-28 13:50:422026-07-16 15:44:35Sheila Gujrathi, M.D.

Sundeep Agrawal, M.D.

https://bhtherapeutics.com/wp-content/uploads/Sundeep_Agrawal.jpg 400 400 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-28 13:45:512026-07-16 15:45:01Sundeep Agrawal, M.D.

Timothy Stubbs, M.D.

https://bhtherapeutics.com/wp-content/uploads/Timothy_Stubbs.jpg 400 400 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-28 13:40:012026-07-16 15:45:43Timothy Stubbs, M.D.

Y. Peter Li, Ph.D., MBA

https://bhtherapeutics.com/wp-content/uploads/Peter_Li-BOD.jpg 400 400 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2024-05-28 13:30:142026-05-19 14:45:54Y. Peter Li, Ph.D., MBA
© 2026 BlossomHill Therapeutics, Inc. | Terms of Service | Privacy Notice
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only